Related Experiment Video

Updated: May 1, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

7.8K

Novel genetic targets in endometrial cancer

Daphne W Bell1

  • 1National Human Genome Research Institute/NIH , Bethesda, MD , USA belldaph@mail.nih.gov.

Expert Opinion on Therapeutic Targets
|April 23, 2014
PubMed

Insights

New genomic targets in endometrial cancer (EC) offer hope for targeted therapies. Research identifies novel mutated genes driving EC, paving the way for personalized treatment strategies.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Research

Background:

  • Endometrial cancer (EC) causes significant global mortality, necessitating deeper understanding of its genomic drivers.
  • Next-generation sequencing (NGS) has been pivotal since 2012 in elucidating the mutational landscape of EC.
  • Prior knowledge of genetic targets in serous and endometrioid ECs has been validated and expanded.

Discussion:

  • Novel significantly mutated genes have been identified in serous and endometrioid ECs.
  • These novel genetic targets represent potential candidate cancer genes.
  • The identified genes are summarized based on unifying functional characteristics.

Key Insights:

  • NGS studies have confirmed known EC genetic targets.
  • New candidate cancer genes driving EC tumorigenesis have been discovered.
  • Understanding these novel targets is crucial for developing subset-specific therapies.

Outlook:

  • Future genomic studies are expected to fill current knowledge gaps in EC.
  • Further research will refine the understanding of novel genetic targets.
  • This work lays the foundation for advancing targeted EC treatment options.
Keywords:
endometrialgenemutationuterine

More Related Videos

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.9K
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis08:16

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

7.9K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K